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ABSTRACT: 
Through the example of a “regulatory ranking” – an index produced with the aim to regulate the 
pharmaceutical market by pushing companies in the direction of providing greater access to medicine 
in developing countries – we discuss indexing and ranking as infrastructural processes which inscribe 
global problem spaces as unfolding actionable territories for market intervention. We reflect on the 
“Indexal thinking” which structures and informs regulatory rankings - their aspiration to align the 
interests of different stakeholders and to entice competition among the ranked companies. We 
foreground the infrastructural work through which such ambitions are enacted, detailing processes of 
infrastructural layering/collage and patchwork through which analysts naturalize/denaturalize various 
contested categories in the ranking’s territory. We reflect on the consequences of such attempts at 
reconfiguring global topologies for the problems these governance initiatives seek to address. 
 
KEYWORDS:  
1. ranking 
2. infrastructure 
3. global 
4. territorialization 
5. topology 
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Introduction 
Rankings are expressions of an ascending mode of social organization by means of commensuration 
and competition (Espeland & Sauder, 2007; Espeland & Stevens, 1998; Jeacle & Carter, 2011; 
Kornberger & Carter, 2010; Mehrpouya & Samiolo, 2016; Pollock & D’Adderio, 2012; Sauder & 
Espeland, 2009; Scott & Orlikowski, 2012). Their diffusion marks the rise of benchmarking as the 
hallmark of 21st century forms of rule (Brown, 2015; Bruno, 2009; Bruno & Didier, 2015; Davies, 2014; 
Larner & Le Heron, 2004). Rankings are, in other words, prominent examples of the expansion and 
intensification of forms of “market thinking” in the calculative infrastructures of governance.  
While we have gained fundamental insights into how rankings produce new configurations of 
discipline and decoupling (Sauder & Espeland, 2009) and invite a whole array of reactivity and 
reflexivity patterns from individuals and organizations (Espeland & Sauder, 2007; Pollock, D’Adderio, 
Williams, & Leforestier, 2018), the ways in which rankings are involved in bringing about new 
territories and scripts for action in different governance settings warrant further interrogating. This is 
especially the case given the increasing deployment of rankings in various facets of regulatory 
capitalism (Levi-Faur, 2005), as regulatory instruments used to harness competition to various social 
goals (Mehrpouya & Samiolo, 2016).  
We attend to these issues by focusing on the information and calculative infrastructures 
underlying a ranking – known as the Access to Medicine Index – that aims to improve access to 
medicine in poor countries by building consensus among stakeholders and by enacting a competitive 
game among the 20 largest pharmaceutical companies variously active in those countries. We engage 
in the “infrastructural inversion” (Bowker & Carlson, 1994) of such ranking, attending to those 
“technologies and arrangements that, by design and by habit, tend to fade into the woodwork” 
(Bowker & Star, 2000, p. 34). We bring to fore the “thinking” aspects of infrastructure, attending to 
the governance aspirations, ideas and programs – governing global health by competition and 
consensus – which infuse the classifications, categorical work and patterns of relationality underlying 
this particular ranking. We examine how this ranking, as “product and process” (Star & Ruhleder, 1996, 
p. 111), “thinks” that which it classifies, measures and seeks to order, and how such thinking informs 
and transforms the ranking itself and inscribes the territories and agentic capabilities of those being 
ranked. 
In particular, we focus here not so much on the consequences of rankings for concrete 
individuals and organizations, but on the ways in which the infrastructural processes underlying 
rankings generate particular scripts of action and configure the problem spaces onto which such action 
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is projected, inviting certain possibilities for deliberation and intervention at the expense of other 
possibilities.  
The ranking examined here, for the purposes of selecting, comparing, scoring and ranking 
companies along the lines of dozens of indicators, is “invisibly supported” (Star, 1999) by existing 
classification systems drawn from international health policy and development debates. It operates 
through the articulation – at times an uneasy one – of such classification systems. This nested 
infrastructural arrangement has evolved over time in a more or less explicit conversation with those 
debates, selectively absorbing their programs and categories, but also provoking at times the 
disruption of existing categories and their underlying assumptions. The result is a particular topology 
(Collier, 2009; Lury, Parisi & Terranova, 2012) in which access to medicine as a problem space is 
constantly reconfigured and rendered actionable in particular ways. 
Analyzing such topology requires attending to the territorializing role (Mennicken & Miller, 
2012; Miller & Power, 2013) of rankings and of the infrastructures which make them up. Paraphrasing 
Miller and Power, we argue that rankings are “deeply involved in constituting the spaces in which 
[they are] active” (p. 577), and in so doing they can shape at once, in a mutually constitutive, open-
ended fashion, spaces of intervention and the subjects of those interventions (Miller, 1992). 
Stuart Elden (2013) has recently suggested that the notion of territory has been largely 
overlooked from a conceptual standpoint, despite its centrality to disciplines like geography, 
international relations and politics. Territory is usually understood as a bounded space within which 
certain forms of power are exercised, but little attention is paid to the “conditions of possibility of 
such a configuration” (Elden, 2013, p. 3). As Elden notes, at the same time when the calculated 
government of populations emerged within modern forms of government, territory co-emerged as a 
political technology going hand in hand with biopolitical tools for the management of populations. To 
govern the latter, the state had to begin to analyze its “territory”. Territory emerged as “a rendering 
of the emergent concept of ‘space’ as a political category: owned, distributed, mapped, calculated, 
bordered, and controlled” (Elden, 2007, p. 578). Territory “is not simply an object: the outcome of 
actions conducted toward it or some previously supposedly neutral area. Territory is itself a process, 
made and remade, shaped and shaping, active and reactive” (2013, p. 17).  
As much as “[t]he idea of a territory as a bounded space under the control of a group of people, 
usually a state, is therefore historically produced” (2007, p. 322), the post-national, global territory 
produced by contemporary governance discourses is a historical creation to be investigated in terms 
of the technologies which sustain it and reproduce it, and of the subjectivities which are made to 
unfold in it (Larner & Walters, 2004). This is even more the case when such space is non-hierarchical, 
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de-centered, and organized like a platform which invites and entices certain relations to form rather 
than directing them from a center (Kornberger et al., 2017).  
The sphere of the global is often imagined as a “homogeneous, calculable space”, an “abstract 
space we have imposed over the world”, which is “taken more and more as real in itself, rather than 
as a reflection of something below it, something that it seeks to represent” (Elden, 2005, p. 16). This 
idealized, calculable, Cartesian space “becomes territory through acts of bounding and making visible” 
(Corner, 1999, p. 222, cited in Elden, 2013, p. 326), and processes of composing and binding together 
its elements according to specific rationales (Collier, 2009). That is, contrary to a common tendency 
to think the “global” as the outcome of a process of abstraction and de-territorialization, attention 
should be paid to the calculative practices whereby the global is re-territorialized in ways that 
transcend the boundaries of nation states. As Escobar put it, “[w]hen a border is eliminated, it 
reappears somewhere else” (2001, p. 139), delivering new politics of visibility, inclusion and exclusion. 
Processes of territorialization can be grasped through the lenses of infrastructure (Harvey, 
2012), attending to how infrastructures “make up and undo state-space through the ways in which 
they both posit and unsettle territories and populations, work across local, national and international 
spaces of law, history and aspiration, bringing past and future, interior and exterior together” (p. 89). 
It is to the role of rankings and their underlying infrastructures in these territorializing dynamics that 
we draw attention here – how rankings demarcate, calculate and sort out “global” problem spaces, 
making them visible and actionable in particular ways, binding together the actors and spaces of global 
governance in territorialization processes. 
Rankings are becoming preferred ways of “knowing the global through calculative practices”, 
thus allowing “the emergence of a global economic imaginary” (Larner & Le Heron, 2004, p. 219) 
centered on notions of continuity and change (Lury et al., 2012). By virtue of “practices of sorting, 
naming, numbering, comparing, listing, and calculating”, rankings have the effect “to introduce new 
continuities into a discontinuous world by establishing equivalences or similitudes, and to make and 
mark discontinuities through repeated contrasts” (Lury et al., 2012, p. 4; see also Espeland & Sauder, 
2007). As Lury and colleagues note, this amounts to a radical intensification of patterns of relationality 
in the guise of continuous comparisons, in which “change is established as constant, normal and 
immanent” and “forms of economic, political and cultural life are identified and made legible in terms 
of their capacities for change” (p. 4; see also Thrift, 2004). Ranking itself emerges as an unfolding 
product and process, constantly moving with that which it seeks to move.  
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Regulatory ranking and “indexal thinking” 
Rankings have become popular ways of “fixing” the global market by seeking to create “markets for 
collective concerns” (Frankel, Ossandon, & Pallesen, 2016). They are frequently mobilized as forms of 
soft regulation pursuing the achievement of particular social goals by means of competitive pressures. 
Such mobilization is more and more visible in transnational governance, where several “regulatory 
rankings” (Mehrpouya & Samiolo, 2016) have proliferated as forms of civil regulation (Vogel, 2008) in 
the attempt to “rein in” multinational corporations, resorting to competition as a tool to achieve 
solutions to socio-economic problems perceived as “global”.  
The use of rankings in the regulation of public goods has expanded rapidly in terms of the 
number of such devices and the public goods that they aim to influence. Some prominent “regulatory 
rankings” include: Access to Nutrition Index, Access to Diagnostics Index, Responsible Mining Index, 
Access to Seeds Index, Aid Transparency Index, Carbon Disclosure Project, Corporate Human Rights 
Benchmark, World Benchmarking Alliance, and the Access to Medicine Index (examined here). These 
devices tend to share similar characteristics: they are developed by private organizations with no 
public mandate, they are financed by powerful funding agencies (frequently the Bill and Melinda Gates 
Foundation and European Development Agencies), they aim to define the responsibility of a category 
of organizations vis-à-vis certain public goods, they involve rituals of stakeholder consultation to 
mediate between competing views and to set a “middle ground” for measurement, they measure the 
“performance” of their targets with regards to how well they comply with the “stakeholder 
expectations” and publish the results of their performance measurement in the form of an index to 
entice competition. Such regulatory rankings are now emerging as a field of related information and 
calculative infrastructures with increasingly shared norms of practice. Second-order infrastructures 
such as “Rate the Raters” (SustainAbility, 2014), which evaluates various regulatory rankings, have 
further accentuated the normalization of best practices across this field.  
Regulatory rankings have specific characteristics that make them stand out from an 
infrastructural perspective. First, they frequently operate in divided and highly contentious fields, 
where certain social values are seen as threatened by global market processes transcending state 
regulation. The stakeholder consultation processes they engage with aim to mend broken stakeholder 
relations and debates about the underlying public good and to build a consensus. The measurement 
apparatus of these devices is situated at the midst of such stakeholder politics and consensus-building, 
civilizing agendas, in which passions are deemed in need taming and interests in need of aligning 
(Hirschman, 1977). As a result, regulatory rankings normally take the form of an index of performance 
indicators seeking to represent and line up the interests of different stakeholders. Indexing promotes 
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the mutual taming of the passions of corporate greed and those of civil society activism (Hirschman, 
1977), turning them into rationalized and well-aligned interests represented by different performance 
indicators. The weighted average performance of each organization ranked (the single figure which is 
fed into the final ranking) thus underpins a certain balance of interests – a deceptively simple and 
often fragile politics of indexing as a process of interest alignment.  
The small size of the organizations that frequently develop such rankings relative to the global 
companies they seek to influence further accentuates their political fragility. As a result, regulatory 
rankings and their underlying infrastructures are particularly exposed to political “shocks” and 
breakdowns. This leads to frequent episodes where the invisible and ubiquitous categories they 
operate with become visible (Bowker & Star, 2000). The possibility to absorb such shocks is 
nonetheless woven in their infrastructural fabric; indices, especially when including large numbers of 
indicators, are well geared to absorb shocks affecting individual indicators, as the weight of each 
indicator may well be of little relevance to the final score. 
Another significant feature of regulatory rankings is that besides their representational agenda 
(typical of transparency initiatives) they also have a more explicit interventional agenda. In other 
words, they openly mobilize the ranking mechanism to try and influence the behavior of their targets. 
They do not simply aim to inform interested parties through ranking, but to transform the ranked. 
They are designed to optimize possibilities of behavioral change. Measurement along the lines of 
various categories is conducted with the aspiration to compile scores and ranks that maximize the 
possibly of the targets competing against each other. Their calculations are ultimately calculations of 
agency, promoting particular notions of the ranked organizations as competing “actors” (Meyer & 
Jepperson, 2000) constantly moving in a trajectory of improvement. Rankings insert the organizations 
they rank into “differentiated hierarchies” in which the ranked are expected “to constantly reinvent 
themselves and remobilize their efforts” (Larner & Le Heron, 2004, p. 215).  
Rankings, in other words, express capitalism’s “will to progress” (Fourcade, 2018) in the guise 
of benchmarking and performance measurement exercises in which “best practices” are defined and 
constantly re-set as moving targets. As a result, such initiatives rely heavily on company innovation as 
the expression of the “exploratory epistemological quality” often ascribed to competition (Davies, 
2014, p. 57). Indexing, as a line-up of performance indicators, allows to order and give intelligibility to 
company practices so as to turn them into regulatory standards, demarcating the innovative and the 
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“best” from the rest. This creates calculable and actionable entry points into an otherwise intractable 
space and allows to project from such points a trajectory of improvement1.  
Furthermore, for the excitement of ranking and performance measurement to materialize, for 
the ranking to matter to its targets and succeed in enticing competition, it should be consumed across 
the polity by relevant constituencies. Regulatory rankings thus take the form of an “engineered 
boundary object” (Bowker & Star, 2000) aspiring to have enough “symbolic and material” plasticity to 
be used among diverse communities of practice, such as regulators, investors, NGOs and the media, 
orchestrating attention, excitement and information usefulness around the performance calculations 
produced. Only thus can competition operate as a regulatory mechanism. 
Based on the above, we refer to regulatory rankings’ preoccupation with balancing interests 
and enticing competition as “Indexal thinking”. In what follows, we detail how this indexal thinking 
structures the “acts of demarcation” (Lezaun, 2006) that (re)define the layered boundaries of the 
global problem space of access to medicine. We illustrate how ranking contributes to the expansion 
and elaboration of corporate actorhood (Bromley & Sharkey, 2017; Meyer & Jepperson, 2000), and 
territorializes the problem space of access to medicine as a “global playground”.  
 
Access to Medicine as a global problem space 
The problem of access to medicine has a long trajectory of formalization and rationalization, starting 
as a list of medicines half a century ago (the “essential drugs list” (EDL) of the World Health 
Organization (WHO), first issued in 1977) to become today a set of variously related problematics, in 
which the role of the market in providing medicines and the scope of public policies in ensuring access 
to health have not ceased to be controversial.  
The EDL is aimed at guiding WHO member states in defining their procurement priorities. It has 
promoted the notion that some medicines are more essential than others, highlighting that many 
medicines (including expensive patented products) in developing countries are not “essential”, while 
certain essential drugs (mostly cheaper off-patent formulations) do not reach populations at need. Its 
issue, which threatened the interests of pharmaceutical companies, was followed by decades of 
politicization of access to medicine as a new problem space transcending individual countries (Greene, 
                                                          
1 Indexing, at its core, is a way of tracing a path of action, of planning a journey through a complex territory. The 
first indices, the book indices which emerged with the invention of the printing press, seem to have been born 
as answers to an information overload, as ways to map a body of knowledge perceived as intractable and 
inaccessible and make it easier to memorize and master (Sttdexi, 2016). This very simple argument points to the 
role of indices in mapping knowledge perceived as inaccessible, too vast and intricate. 
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2011; Laing, Waning, Gray, Ford, & t Hoen, 2003). This highly consequential list, which is continuously 
updated and known today as “essential medicines list” (EML), led in 1980s to a major pushback by the 
pharmaceutical industry and the US government, which cut its funding of the WHO for two years 
(Levison & Laing, 2003). This culminated into change of WHO directorship and demotion of the EDL 
program in the WHO structure.  
In the 1980s and 1990s, HIV/AIDS led to a radical intensification and reconfiguration of this 
politicization. On the one hand, the dramatic spreading of the virus in some low/medium income 
countries increased their attractiveness for the pharmaceutical companies as fast expanding 
“emerging” markets. On the other hand, the virus created urgency around the need for a range of 
new, patented and highly unaffordable HIV/AIDS medicines for large pockets of poor populations (t 
Hoen et al., 2003). HIV/AIDS, in other words, brought the business model of western pharmaceutical 
corporations to new non-Western geographies, generating new problem spaces such as equitable 
pricing and patenting of HIV/AIDS medicines. HIV/AIDS has been one of the factors leading to a push 
by Western governments, where most of the largest pharmaceutical companies are based, for 
stringent patent enforcement around the world, which materialized in the form of the TRIPS (trade-
related aspects of intellectual property rights) agreement, spearheaded by the World Trade 
Organization in 1994 (t Hoen et al., 2003).  
As a trade agreement that forces member states to implement regulatory platforms for the 
enforcement of intellectual property rights, TRIPS contributes to lift the access to medicine problem 
from the international to the global level. The WHO’s EDL/EML has been developed for the nation 
state as primary user, in order to guide the development of national health policies. The WTO’s TRIPS 
agreement, too, stems from the inter-governmental sphere and seeks to guide national policies, but 
as a binding harmonization project to remove barriers to trade, it mobilizes national policies in favor 
of the property rights of global companies, harnessing national sovereignties to the creation of 
“global” markets. As Traub-Werner notes, “projects of harmonization written into trade agreements 
make commensurable spaces thinkable at a supranational scale” (2007, p. 1443). With TRIPS, certain 
aspects of access to medicine (in those instances in which it requires to breach the intellectual 
property rights of pharmaceutical companies) become an obstacle to the free trade, bringing to the 
fore the pharmaceutical corporation as a sort of competing sovereignty to that of the nation state (a 
notable example is the lawsuit filed by 39 large pharmaceutical companies against the government of 
Nelson Mandela in South Africa in the late 1990s for its imports of generic anti-retroviral drugs). In 
this shift, the access to medicine problem escalates into a transnational arena of clashing 
sovereignties.  
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In late 1990s rising “global” civil society actors such as Doctors Without Borders played a key 
role in driving such clash, documenting the detrimental effects of patent enforcement for access to 
medicine across the world, and enrolling various national entities in the global “access to medicine 
campaign”, which has now developed into a dense transnational community (Greene, 2011).  
In the early 2000s, for the first time, the notion of a global space of need for access to medicine 
could be calculated and summed up as a single figure, defined by the United Nations as “2 billion 
people lacking access”. This number has since played a central role for various access to medicine 
organizations, including the Access to Medicine Foundation, helping them carve out and motivate 
their diverse missions within this field.  
 
The Access to Medicine Index  
Since its launch in 2005, through a bi-annual stakeholder consultation and ranking exercise, the Access 
to Medicine Index (from now on “the Index”) has attempted to reconcile the competing/conflicting 
views of NGOs, investors, Southern and Western governments, IGOs (especially the WHO but also the 
United Nations), patients, and companies themselves, guided by the urge to carve out a space of 
consensus in which measurement could take place. Now it its sixth iteration, the Index has become a 
central arena for debating the responsibilities of pharmaceutical companies with regards to access to 
medicine and their comparative performance in this area. 
The Access to Medicine Foundation, based in the Netherlands, has taken on this consensus 
building role against the background of a field fraught with litigation and scandals, with 
pharmaceutical companies pushing for more stringent enforcement of patents, and Southern 
governments, NGOs and generics companies (mostly Indian) campaigning against it (t Hoen et al., 
2003). Patents are only one of the many issues (alongside affordable pricing, research and 
development for diseases of the poor – or “neglected diseases”, marketing, lobbying & competitive 
practices, and the like) forming the blurred boundaries of the problem space of access to medicine. 
The Index Methodology Report, issued every two years, actively seeks to demarcate such problem 
space, and the contested responsibilities of pharmaceutical companies in addressing it, by listing the 
diseases and countries which form its scope and a set of indicators to measure companies’ behavior 
within that scope.  
Each Index cycle starts with stakeholder consultation leading to the launch of the updated 
Methodology Report. This is followed by several months of data collection, analysis and scoring, which 
culminate in the release of a ranking of 20 of the largest pharmaceutical companies, seeking to 
RUNNING HEADER: Indexal Thinking 
 
 11 
mobilize market forces and the ascribed competitive agency of firms to entice them to move towards 
their “stakeholder-mandated” responsibilities. In this governance scheme, firms are deemed to care 
about the ranking and engage in “virtuous competition” if powerful stakeholders, including investors, 
regulators and large NGOs, use the Index in their actions vis-à-vis the industry.  
In order to create zero-sum games among the ranked organizations (Espeland & Sauder, 2007; 
Werron, 2015) such organizations need to be made comparable by means of common measures 
(Espeland & Stevens, 1998). A key measure chosen in the case of the Access to Medicine Index as the 
basis for the inclusion of companies in the ranking was company size, measured in terms of 
pharmaceutical revenues. The company scope chosen as relevant to the global problem of access to 
medicine was thus based on a simple financial accounting measure. Yet this measure brought into the 
competitive space of the Index companies with widely different business models, whose 
commensuration has been at times problematic. For example, the Japanese companies, which have 
been included in the Index since 2010, had limited activity outside the Japanese and US markets. They 
thus demanded to be held to a different standard compared to the Western companies in the Index, 
as their impact on global access to medicine was necessarily reduced by their limited geographical 
footprint. However, the Index methodology rejected this kind of reasoning, promoting instead the 
view that such companies’ limited geographical scope was a sign of lack of attention to the social case 
for access to medicine, and, importantly, it meant missing out on growth opportunities in those 
emerging markets (business case).  
Using revenues as a basis for commensuration tossed these companies into a global “level 
playing field” in which access to medicine is framed as a global social problem and a global business 
opportunity demanding their strategic efforts. The Index thus sustains a discursive realm in which the 
strategic horizon of pharmaceutical companies is expanded, casting those who do not take up the 
challenge of emerging markets as losers in a global game. A certain global imagery and the 
benchmarking logic permeating the ranking thus contribute to turn an abstract calculable space – a 
list of countries – into a territory that can be governed according to specific rationales, where the 
health of different populations is matched to the business model of global pharmaceutical companies 
(as we detail below), and where the ascribed agentic features of the latter are expanded in the 
process.  
The latest Methodology Report defines 77 diseases as Index Diseases and sets 106 countries 
as Index Countries. Companies are ranked for their activities across 69 indicators organized under 
seven Technical Areas. In the process of the formulation of these indicators, several new technical 
categories have been defined to make diverse and dispersed events and instances of practice tangible, 
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traceable, measurable and comparable at the global level. The Technical Areas used to structure the 
Index’s problem space are listed below. Each comprises several indicators, further categorized under 
Commitments, Transparency, Performance and Innovation indicators (the latter four sub-categories 
are termed “Strategic Pillars”) (ATMF, 2017, p. 8): 
• General Access to Medicine Management 
• Market Influence & Compliance 
• Research & Development 
• Pricing, Manufacturing & Distribution 
• Patents & Licensing 
• Capacity Building 
• Product Donations 
 
The Index’s measurement apparatus has been developed with the imperative of balancing in 
mind. It seeks to “measure in the middle” of a divided stakeholder base. It thus includes indicators 
with stronger or weaker business case attributed to them, which sit uneasily within the same index. 
Companies are to be shown a way forward through the indicators which make up the index, but they 
are also expected to lead the way though the innovative practices those indicators seek to capture. 
The Index set out to harness pharma’s “knowhow” to achieve the United Nations’ Millennium 
Development Goals (and more recently the Sustainable Development Goals) (interview with the 
Founder of the Access to Medicine Foundation, 2013), resorting to competition as a way to produce 
new knowledge (Davies, 2014) and mobilizing market innovation as a regulatory mechanism (Brown, 
2015).  
Innovation indicators constitute a “Strategic Pillar” within the calculative infrastructure of the 
ranking. The Index analysts actively seek out examples of innovative company practices, which are 
also heavily reflected in the narrative part of the Index Report. The Index tries to detect and integrate 
such emerging practices so that competition can lead to their diffusion in the sector. It “harvests” such 
practices, which are company-specific and often country-specific, from their emplacements, and 
absorbs them into its calculative infrastructure so as to normalize newly expanded scripts for 
corporate action. Innovative company practices are the visible boundary of access to medicine in the 
making, a moving boundary in the trajectory of improvement traced by the Index. In this way, the 
Index absorbs the new, and the alleged spontaneity of “free” market innovation is turned into a soft 
regulatory standard. 
------------------------------------------------------- 
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Please insert figure 1. about here. 
------------------------------------------------------- 
In each iteration of the Index, the Methodology Report highlights this trajectory, (re)adjusting 
the calculative boundaries of Index countries, diseases and indicators in order to reflect improvements 
from previous iterations and create the scope for further ones. In so doing, it continuously 
(re)establishes the high priority areas for access to medicine and the more urgent stakeholder 
expectations from the pharmaceutical companies. The territorializing work at play in re-setting the 
boundaries of the access to medicine problem space constantly redefines the strategic horizon of the 
corporation whilst also creating a layering of superposing territories where “high priority” categories 
are selectively foregrounded within such problem space. It is to this territorializing work that we now 
turn. 
 
Territorializing a Global Need 
The first iteration of the Index (2008) did not have a well-demarcated territory. It captured and scored 
all company activities that seemed to be broadly linked to the accessibility of needed medicines in 
poor countries and communities. The territory and content of access to medicine in Index 2008 was, 
as a result, highly reliant on the practices of the companies. Since Index 2010, the Index analysts have 
set out clear boundaries around the geographical and disease scope of the Index. This has helped 
define the range of relevant practices for scoring all twenty companies and establish the Index as a 
level-playing field. The setting of the disease and country scope also aimed to concretize the areas of 
need separately from the responsibility of the companies (defined by the Index indicators). The 
competitive mechanism underlying the Index would then help stretch the boundaries of company 
responsibility in the direction of covering the full territory of need over several iterations of the Index.   
The Access to Medicine Index relies on various secondary global infrastructures, such as the 
WHO’s Global Burden of Disease database, the WHO’s International Classification of Diseases, United 
Nations’ Human Development Index and the World Bank’s Country Income Classifications, to 
concretize the geographical, disease and product boundaries of this need. Over the years, the Index 
analysts have used different ways of combining these classifications in a way that would be acceptable 
to the Index’s constituencies, including the WHO, the broader global access to medicine community 
but also the companies themselves. At stake are the normative foundations of such secondary 
infrastructures, and how they can be mobilized in a way that would be consistent with the intuition of 
the analysts and the diverging claims of various constituencies. 
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Infrastructural Patchwork – Expanding the Diseases of the Poor 
The boundaries of the access to medicine need have been frequently contested and adjusted over the 
years. The country scope and disease scope of the Index have both expanded over time (from 88 
countries in Index 2010 to 106 in Index 2018, and from 33 diseases in Index 2010 to 77 diseases in 
Index 2018). At stake has been not only setting new areas of company responsibility, but more 
fundamentally in some cases, the definition of what a disease is.  
The disease scope has been defined since Index 2010 based on the WHO’s International 
Classification of Diseases (ICD), its “Global Burden of Disease” database. The former attempts to 
classify all human ailing and the latter conducts a measurement of the mortality and morbidity burden 
each disease causes in each country based on Disability-Adjusted Life Years (DALYs) lost to the disease. 
DALYs are measured at country level and aim to influence national policies. To use them for defining 
the “global” territory of the access to medicine problem, and to make them relevant to the “global 
corporation”, the analysts aggregate the DALY figures across all Index Countries. The Index then covers 
the top non-communicable diseases (currently fourteen) and top communicable diseases (currently 
twenty-one) based on these figures, and adds to the list certain maternal and neonatal health 
conditions (currently ten) and the so-called “neglected tropical diseases” (currently twenty). The latter 
are insect-borne diseases mostly exclusive to tropical climates. Several of these diseases do not have 
very high DALYs associated to them because of the limited number of countries where they occur. To 
cover them, the Index has to make an exception to the DALY-based calculation, referring to the WHO’s 
focus on these diseases to justify the exception.  
The disease scope of the Index is fundamentally structured around the goal to set a clear and 
calculable global space that would provide the level-playing field in which companies, enticed by their 
single global score and ranking, could engage in competition. As a result, diseases that remain too 
localized and do not lend themselves to global comparisons tend to be excluded. 
This clear and calculable space has been subject to multiple adjustments over the years. One 
important debate has been the differentiation between communicable (or infectious) diseases, 
including Tuberculosis, Malaria, HIV/AIDS, neonatal infections and Hepatitis, and non-communicable 
diseases such as cardiovascular diseases, diabetes, cancers and psychological diseases. The former 
have been historically referred to as the diseases of the poor and the latter as those of rich countries. 
Lack of health infrastructure to deal with non-communicable diseases (mostly chronic) and low life-
expectancy in “poor countries” (people dying before they can be affected by major non-communicable 
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diseases) have been two arguments behind focusing on communicable diseases. The access to 
medicine need was thus originally associated with poverty and its most visible correlate – mortality. 
However, most of the drug development of the large western pharmaceutical companies has 
been focused on the lucrative non-communicable diseases markets. The notion of “emerging markets” 
first, and the rise of the BRICS category afterwards (Fourcade, 2013; Wansleben, 2013), have led to a 
reframing of the notion of “poor countries”. In these “emerging” economies part of the society has 
already “emerged” and as a result is affected by non-communicable diseases, while the other part is 
still “poor” and afflicted with communicable diseases. In global health language, this is referred to as 
“the Double Burden of Disease”. The language of Double Burden of Disease, in other words, led to a 
re-territorializing of the diseases of the poor, with non-communicable diseases moving increasingly to 
the center stage. Since around 2010, the WHO has put much more emphasis on non-communicable 
diseases in the debates around access to medicine. Over the years, the Index has followed suit and 
has expanded its coverage of non-communicable diseases. Attention to “emerging economies” and 
non-communicable diseases has also helped emphasize the “business case” for access to medicine in 
a way that would resonate with investors and companies themselves. As demonstrative examples, 
below we elaborate on the territorialization work involved with regards to contraceptives, hepatitis 
and cancers.  
As to contraceptives, they were not covered in the first iterations of the Index (2008 and 2010), 
because they did not address a “disease” as defined by the ICD. Furthermore, contraceptives were 
considered problematic in areas where HIV/AIDS was endemic, because they could lead to decreased 
use of condoms and some studies associated injectable contraceptives with increased risk of the 
transfer of HIV (Heffron et al., 2012). The advocates of inclusion in contrast emphasized the 
importance of contraceptives to decreasing maternal/infant mortality. One key group advocating the 
inclusion comprised of companies active in production and distribution of contraceptives, such as 
Bayer, which were eager to see their access initiatives in this area recognized. From Index 2012, 
contraceptives have been included through association with maternal morbidity and mortality, which 
are classified under the ICD (arguing that unwanted pregnancies can lead to precarious maternal care 
and maternal morbidity/mortality). Contraceptives were an alien category “patched” into the 
information infrastructure of the Index and “naturalized” through its “filiation” with a category already 
existing in the infrastructure – that is, maternal health. Such filiation establishes a new pattern of 
relationality, a causality relation between an issue space that needs to be naturalized (in this case 
contraceptives) and categories that are already naturalized (in this case maternal health).   
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Hepatitis is another disease whose inclusion has taken several years and intense categorical 
work to be settled. Based on burden of diseases calculated in DALYs, different types of Hepatitis had 
to be excluded because neither of them causes sufficient mortality in Index countries to be placed 
among the top communicable diseases. With Index 2010, however, the analyst team decided to 
aggregate different Hepatitis categories (B and C) and cover them under Cirrhosis of liver, which can 
be caused by Hepatitis but has also many other causes such as alcohol induced fatty liver. The 2014 
Index Methodology Report mentions: “coverage of cirrhosis of the liver has been broadened to include 
chronic viral hepatitis, as it can develop into cirrhosis of the liver” (ATMF, 2013, p. 15). This was 
however a problematic classification, because Hepatitis is a “communicable” or infectious disease, 
while Cirrhosis of the liver is classified by the WHO’s ICD as a non-communicable disease. This patching 
of Hepatitis into the Index’s classification system based on a causality relation happened at a time 
when many companies were active in developing vaccines/drugs for Hepatitis, and this particular 
illness was also being emphasized by the WHO. This classification was however problematic because 
the WHO and other international organizations articulate their policies based on a strong 
differentiation between communicable diseases and non-communicable diseases. 
As a result of this misclassification issue, in 2018 the approach for coverage of Hepatitis 
changed. Hepatitis B and Hepatitis C were declassified from under Cirrhosis and were instead covered 
as a separate aggregate category of “viral Hepatitis” under communicable diseases (ATMF, 2017, p. 
25). This addressed the classification issue (from non-communicable to communicable disease 
category). Resorting to an aggregate disease category made Hepatitis stand out for the first time in 
the information infrastructure of the Index (where it had previously remained hidden under the 
category of Cirrhosis of liver). As with contraceptives, the inclusion of hepatitis within the Index scope 
involved patchwork based on “naturalization” of hepatitis through “filiation” with existing categories, 
and aggregation of types B and C into one category.  
In the case of cancer, in the earlier iterations of the Index, guided by WHO input, the analyst 
team decided not to cover its remedies. Such drugs were considered expensive, not sufficiently 
efficacious and effective and, importantly, they required diagnostic/therapeutic infrastructure that 
was lacking in many Index countries. The 2010 and 2012 Index Methodology Reports discuss disease 
coverage based on calculations of disease burden, but do not engage in a specific discussion about the 
exclusion of cancers. The Methodology Report for Index 2014 justifies the exclusion of cancer for the 
first time, “as the disaggregated DALY burden for individual forms of cancer did not meet the criteria 
for inclusion (burden of 13,000 DALYs per 100,000)” (ATMF, 2013, p. 15). The Methodology Report for 
Index 2016 clearly acknowledges the stakeholder demands to cover cancers, and the WHO’s increased 
coverage of cancer medicines in its Essential Drugs List. However, the 2016 methodology continued 
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excluding cancers, arguing that “Lower-income countries are less likely to have the support systems 
in place that are needed for effective treatment, and in fact may be more likely to suffer from stock-
outs of the older, generic medicines needed” (ATMF, 2015, p. 13).  
Following the increased emphasis placed on cancers by the WHO, Index 2018 finally started to 
cover them. Cancers have been included as an exception to the calculations. The 2017 Methodology 
Report, while detailing disease burden calculations, mentions that “[a]n exception to this approach is 
cancer: cancer types are included if they (a) have high burdens of disease or (b) have relevant 
medicines on the WHO List of Essential Medicine” (ATMF 2017, p. 25). 
 ------------------------------------------------------- 
Please insert figure 2. about here. 
------------------------------------------------------- 
Cancers, in other words, moved from exclusion based on DALY calculations with no visibility (Index 
2010 and 2012), to visible exclusion based on DALY calculations (Index 2014), to visible exclusion based 
on qualitative arguments (with one page of the Methodology Report for Index 2016 dedicated to the 
issue), to inclusion in Index 2018, based on references to the WHO’s EML. Cancers provide an example 
of infrastructural patchwork involving “denaturalization” of a category through the shrinking of a 
problem space based on calculative disaggregation, followed by its stepwise naturalization into the 
Index territory in subsequent iterations of the Index.   
Such infrastructural patchwork was pervasive in the categorization work of the analysts. 
Analysts resorted to aggregation, disaggregation and filiation to patch or “un-patch” different diseases 
into the Index’s disease scope. Such techniques play an important role in naturalizing and 
denaturalizing different aspects of the access to medicine problem in a conversation with changing 
debates and classifications in the sphere of global health (e.g. Double-Burden of Disease), with 
important consequences for how the various territories and sub-territories of the access to medicine 
need are configured as areas of corporate responsibility and inter-company competition.  
 
Infrastructural Collage - Expanding Geographies of Need 
The country scope of the Index is based on various development and income indicators which are 
defined at country level. As a result, such scope is based on the unit of “countries”, lumping together 
the diverse access to medicine needs of very large and heterogeneous regions and populations, such 
as those of Brazil, Bangladesh and India.  
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The dominant secondary infrastructures in this area are the Country Income classification of the 
World Bank and the Least Developed Countries (LDC) listing and Human Development Index (HDI) of 
the United Nations. These indices provide different visualizations and orderings of countries. The 
World Bank Country Income classification is primarily driven by economic indicators, while the HDI is 
considered as an alternative which aggregates a broader set of social measures pertaining to areas 
such as healthcare, education and governance (with HDI being typically supported by NGOs).  
Since 2010, different forms of “infrastructural collage” have enabled the combination of these 
secondary infrastructures. By infrastructural collage we mean categorical work based on 
superimposition and layering of different secondary infrastructures (see also Reilley & Scheytt, this 
volume), allowing for different ways of combining their respective categorizations, and thus for 
selectively foregrounding certain elements and backgrounding others. 
For Index 2010, analysts included the HDI low and medium development countries, while 
excluding countries with medium-high to high income levels as defined in the World Bank 
classification. The exclusion of medium-high and high income countries was done on the basis that 
these countries have the economic resources to address their healthcare challenges and as a result 
they are not “high priority”. This, however, led to excluding “BRICS countries” such as Brazil and South 
Africa, which have large pockets of poor and uninsured populations, as well as resource-rich Sub-
Saharan countries with major healthcare challenges such as Gambia and Namibia.  
Following the launch of Index 2010, several constituencies voiced criticism of this exclusion. For 
example, the WHO representative expressed concerns about the exclusion because of the centrality 
of such large countries to global health policy and also their large pockets of poor populations. Another 
key voice was that of companies with access to medicine initiatives in those excluded countries, which 
sought to improve their positions in the ranking by having more of their initiatives covered. The 
exclusion of Brazil, for example, led to the exclusion of Merck’s initiatives related to the Human 
Papilloma Virus vaccine (Gardasil) in Brazil.  
As a result of such pressures, since the 2012 the Foundation has adjusted the way it mixes and 
matches those secondary infrastructures for country classification, so as to ensure that its country 
scope is aligned with companies’ practices, perceived access to medicine needs in those countries, 
and related failures in their health infrastructures. This is how the country scope of Index 2018 is 
defined (ATMF, 2018, p. 223): 
The geographic scope for the 2018 Access to Medicine Index comprises 106 countries. All 
countries defined by the World Bank as low income or lower middle-income are included. All 
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countries defined by the UNDP as either low or medium human development are included. This 
ensures that several central measures of human development (life expectancy, education, and 
standard of living) are taken into account. All countries that receive a score of less than 0.6 on 
the UN Inequality-Adjusted Human Development Index are included. This measure takes 
account of how health, education and income are distributed within each country. Finally,  all 
Least Developed Countries (LDCs), as defined by the Committee for  Development Policy of the 
UN Economic and Social Council (ECOSOC), are  Included. 
 
This marks a reconfiguring of the infrastructural collage underlying Index’s country scope. As in Index 
2010, three secondary infrastructures are combined, but this combination is now inclusionary. The 
sets of countries defined by each of the three infrastructures now form a union rather than an 
intersection. In other words, no infrastructure is used to exclude categories in another infrastructure.  
Defining the country scope based on the inclusionary collage of those infrastructures is 
politically less risky; it might lead to territorial “over expansion”, but it is much less likely to lead to 
controversies related to the exclusion of countries, which may stem from pressures from companies 
with initiatives in those countries or from changes to international health policy or development 
classifications. This example illustrates how discrepancies among the Index’s secondary 
infrastructures, their perceived limitations, and pressures from companies are mediated through 
categorical work. Through this process of superimposition and collage, large pockets of population are 
moved in and out of the Index’s scope with each iteration of the Index.  
Interestingly, such processes are mostly expansionary and integrative. The increased coverage 
of diseases and countries is highlighted in the first pages of each Index report and is presented as a 
sign of the Index’s growth and success. Seen from the lenses of “thinking infrastructure”, however, 
this expanding territory can also be seen as a function of the aspiration to govern through competition 
and innovation. When companies create pressures to see the diseases and the countries in which they 
are active recognized, the aspiration to harvest new examples of innovative practices can lead to much 
more intense categorization and classification efforts to evaluate whether those practices can be 
included, causing an overflow of competitive pressures back into infrastructural design. When 
company activities resonate with the international health policy and development debates illustrated 
above, changes to the Index disease and country scope acquire justification and momentum. Such 
resonance solidifies certain implied causality relations, allowing for new patterns of relationality to 
provisionally stabilize. The boundary of the Index, and the access to medicine territory, can thus shift.  
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Indexal Thinking and Global Playgrounds 
Regulatory rankings such as the Access to Medicine Index are at the forefront of attempts to 
manage divisive “global” issues through market-based organizing and to regulate them through 
consensus-building and competition, contributing to the marketization of transnational governance 
regimes (Djelic & Sahlin-Andersson, 2006). They underpin “infrastructures of referentiality” (Latour, 
1999) through which diverse “local” practices become traceable at the global level (Lezaun, 2006). 
Such infrastructures also have the potential to re-territorialize the global by making it actionable 
according to specific rationales, through processes of measurement, comparison and competition 
revolving around those global references.  
We have illustrated how various categorization, classification and commensuration processes 
enabled the transformation of the fragmented and contested problem space of access to medicine 
into an ordered, indexed, calculable and unfolding territory for governing through competition and 
innovation, where the “calculable understanding of [this] space has been extended to the globe” 
(Elden, 2005, p. 2). The infrastructural lens we adopted enabled us to foreground “what makes this 
space possible and therefore allows  it  to  be  produced, reconfigured  and  transformed” (Elden, 2005, 
p. 19), supporting our understanding of the highly performative web of constructs and processes that 
enable, maintain, expand, densify and territorialize the global. 
Our analysis also points to specific ways in which the global as an abstract calculable space may 
be turned into territory through infrastructure: bounding it (through listing countries and diseases to 
be included and excluded), selectively foregrounding its features (e.g. from an exclusive focus on 
mortality to the inclusion of morbidity, introducing certain diseases like neglected tropical diseases by 
exception), and composing and binding these features together (e.g. through categorical patchwork 
and collage) in variable patterns of relationality in which the “thinking” underlying the infrastructure 
temporarily solidifies.  
The “indexal thinking” permeating the ranking, the ambition to govern the global through 
consensus and competition, shapes the emerging territory of access to medicine in important ways. 
Firstly, such territory is configured as a “level playing field” where the competitive game can be 
deemed “fair” (Davies, 2014). For competition to be considered fair, the boundaries of performance 
measurement, including the selection of competitors, have to be clear. The competitors need to know 
who and what is counted or not, to be able to judge the fairness of the comparison. Yet, as the case 
of Japanese companies illustrates, this judgment of fairness and thus the Index territory may well be 
contested. The matching of the “global” competitive field to companies (through commensuration 
based on company revenues) was perceived as unfair by Japanese companies, whose activities tended 
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to be “regional” and less relevant to the Index’s more global scope. Yet, in principle at least, including 
Japanese companies in the Index and holding them to the same standard as other, more global 
companies stretches the strategic horizons and business models of those regional companies, 
generating new external expectations in the name of the global. In this way, the ascribed agentic 
features of participating companies are expanded (Bromley & Sharkey, 2017; Meyer & Jepperson, 
2000). 
Secondly, the aspiration to regulate through competition and establish company innovations as 
industry standards means that the innovative practices signaled by companies are given much 
attention and consideration, leading to an intensification of categorical work. Innovative practices are 
the “cutting edge” through which the boundaries of companies’ responsibilities expand by harnessing 
the market’s imagined creativity and freedom to innovate (Davies, 2014). Corporate actorhood is 
expanded, yet again. The urge to search for and capture new initiatives constantly brings into the field 
of vision of analysts also innovations that fall outside the current scope of the Index. The competitive 
urge enticed by the Index, in other words, overflows back into the Index infrastructure, creating 
pressures at the boundaries of its territory. Such “competitive overflows” are one of the reasons 
behind the gradual expansion of the ranking’s problem space over the years. Absorbing innovations 
into the infrastructure of regulatory rankings is one of the engines behind the amoebic expansion of 
their territories, one which, as we have seen, requires an intensification of categorical work and 
measurement through patchwork and collage.  
As discussed, this work succeeds in moving the boundaries of the access to medicine territory 
when innovative company initiatives find resonance with international health policy and development 
debates and categories, matching areas of need with economic excitement.  
Such excitement, companies’ presumed urge to compete based on which regulation can happen 
through ranking, is enticed by ensuring that the ranking is relevant to important company 
stakeholders. This is a third important aspect of the “indexal thinking” underlying regulatory rankings. 
At stake here is not only carving out a role for the corporation in areas which have been historically 
under the exclusive territory of state sovereignty, replacing the command and control vertical order 
of the latter with the level playing field of competition. Regulatory rankings also attempt to engage 
various stakeholders, including investors, NGOs and Southern governments, whose decisions have the 
power to influence companies. Categories such as “double burden of disease” have been especially 
impactful in terms of moving the boundaries of the Index and reconciling the interests of different 
constituencies. They can appeal not only to health policy communities but also to companies or 
investors (by making drugs developed for Western markets relevant to Index countries), potentially 
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engaging and activating influential groups within the Index’s stakeholder base. Regulatory rankings 
are, in other words, infrastructures in which the behavior of the ranked is calculated as an equation 
of interlinked actors and scripts for action.  
We can think of this evolving territory informed by indexal thinking as a “global playground” in 
which the excitement of competition replaces political conflict in the defense of public goods. The 
boundaries of this playground need to be clearly set, yet moving, as a function of innovation and 
competition and of the orchestration of different actors whose interests and views need aligning and 
whose strategic horizons need expanding through a competitive game. This constant motion, which 
the Index both induces and becomes a product of, has important stakes. Its direction is selective, and 
its changing boundaries carry a politics of inclusion and exclusion.  
The different country classifications used to define the country scope, based on their underlying 
values and calculative regimes, make certain local aspects visible while obscuring others. As shown, 
such secondary infrastructures can be collaged in different ways. In the case of the Index, there has 
been a transition from intersection to union of sets and thus a more inclusionary logic which avoids 
controversial exclusions such as those of Brazil and South Africa in 2010, when intersection was used 
instead. Along similar lines, the disease scope of the Index has evolved in a conversation with 
international health policy debates and categories. These have provided the rules (DALYs) and the 
exceptions (as in the case of neglected tropical diseases) for setting such scope, requiring intense 
infrastructural patchwork to rationalize inclusions and exclusions. Analysts resorted to the aggregation 
and disaggregation of the DALY figures of different diseases, or else to filiation of diseases which are 
outside the Index territory from diseases which are inside it (e.g. filiation of Hepatitis from Cirrhosis), 
to naturalize or de-naturalize particular diseases within the calculative infrastructure of the Index.  
At play in such territorialization is a transformation of the face of the “global poor” and of the 
government of poverty. As shown, there has been a shift in the global health in the articulation of the 
access to medicine need from an almost exclusive focus on communicable diseases to a dual focus on 
communicable and non-communicable diseases, the aforementioned “double burden of disease”, 
which combines the traditional diseases of the “poor” with those of the “rich” Western Countries. This 
integration reflects a more general shift in postcolonial global health discourses, which, contrary to 
their colonial antecedents, are no longer primarily concerned with “converting” the poor to Western 
medical theories and practices in the name of humanitarianism – such conversion is now largely taken 
for granted.  “[T]he goal is no longer to bring modern Western medicine to primitive cultures, but 
rather to furnish them with Western medical technologies in an effort to foster the integration of 
underdeveloped nations into the world capitalist economy” (King, 2002, p. 780). The dominant 
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metaphor of such discourses is, according to King, one of emergence and integration of the poor “into 
global networks of commodity and information exchange” (p. 782), which the Access to Medicine 
Index, as we have seen, is preoccupied with. 
The biopolitical shift from acute to chronic and from mortality to morbidity in international 
health policy, predicated on a discourse of emergence from poverty and partial improvement, has 
made the vast volumes of pharmaceutical products directed at Western markets become relevant for 
the “Index Countries”. In this respect, addressing access to medicine as a “global problem” has become 
more financially exciting for companies and investors. The promise of “unknown opportunities” which 
characterizes the rhetoric of BRICS (Wansleben, 2013) is thus realized. “Emerging markets” have acted 
as crucial bridging concepts through which the problems of the poor have been articulated and 
integrated into those of the Western countries, with the indirect consequence of bringing the problem 
space of access to medicine closer to the business model of Western companies. Emerging economies 
are especially “actionable” from the perspective of the industry; they are instances in which the formal 
balance of interests sought by the Index turns into an alignment in which what can be easily aligned 
to global health policy and development discourses stands out and succeeds in moving the boundaries 
of the Index. 
To conclude, through the example of a regulatory ranking, our study has sought to illustrate the 
important role that seemingly mundane infrastructural processes play in defining and transforming 
the territories of global governance. Our preoccupation has been the ways in which rankings, as 
“thinking infrastructures”, affect the territories of need that global corporations are deemed to help 
address, making those territories actionable according to the logics of consensus, competition and 
innovation, expanding the ascribed responsibilities and strategic horizons of those corporations in the 
process.  
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Figure 1. Access to Medicine Index 2018 ranking graph (ATMF, 2018) 
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Figure 2. Process for inclusion of diseases in Index Territory (ATMF, 2017, pp. 25-26) 
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